LEWIS ANTIGEN EXPRESSION AND PATHOGENESIS OF H PYORI

幽门螺杆菌的路易斯抗原表达和发病机制

基本信息

  • 批准号:
    2887493
  • 负责人:
  • 金额:
    $ 15.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-09-30 至 2001-08-31
  • 项目状态:
    已结题

项目摘要

Helicobacter pylori is a gram-negative bacterium that lives in the mucus layer of the stomach lining and is the major cause of chronic gastritis and peptic ulcer disease, which is a major risk factor for gastric cancer. The recent realization of the importance of H. pylori as a human pathogen has focused attention on this infectious disease: It is now well established that it is the infection that should be eradicated, not just the symptoms treated. Vaccines composed of whole Helicobacter (either whole-cell sonicates or heat-killed bacterial) alone or in combination with bacterial toxin adjuvant have been shown to provide immunity in several animal models of infection. One major problem with this approach is that factors inherent in H. pylori may cause inflammation and an inappropriate immune response. One such factor is lipopolysaccharide (LPS), which is known to mediate inflammation and induce cytokine release. The structure of the O polysaccharide portion of H. pylori LPS has recently been elucidated for three different strains; each was found to be unique and to terminate in Lewis x and/or Lewis y blood group antigens. H. pylori is the first bacterium found to express these Lewis antigen determinants. Lewis x and Lewis are found on normal gastric tissue but are more abundant on certain tumor cells. Several hypotheses for the role of H. pylori-borne blood group antigens during H. pylori infection can be considered. They may (1) serve as molecular mimics, blinding the host to H. pylori and thereby helping this pathogen to evade the immune system; (2) act as adhesins interacting with cellular receptors on the gastric mucosa; (3) stimulate autoimmune reactions that cause tissue damage and thus contribute to the disease state; or (4) elicit oral tolerance and thus lead to a decreased ability of the host to clear tumors that are also marked by Lewis antigens. None of thee hypotheses is mutually exclusive, nor would any of them fail to contribute to damage to the host. The long-term goal of this new H. pylori research program is to determine the role of Lewis antigens in the pathogenesis and carcinogenic potential of this bacterium. Specifically, a serotyping system for H. pylori based on Lewis antigen expression will be established to type strains from various clinical sources. In addition, H. pylori strains efficient in the production of Lewis antigens will be constructed and evaluated for their pathogenic attributes and their potential as vaccine candidates.
幽门螺杆菌是一种革兰氏阴性细菌, 胃粘膜的粘液层,是慢性 胃炎和消化性溃疡疾病,这是一个主要的危险因素, 胃癌 近年来人们对H.幽门 作为一种人类病原体,人们把注意力集中在这种传染病上: 现在已经很好地确定,应该是感染 根除,而不仅仅是治疗的症状。 疫苗组成 完整螺杆菌(全细胞超声处理或热灭活细菌) 单独或与细菌毒素佐剂组合使用 在几种动物感染模型中提供免疫力。 一个主要 这种方法的问题是H.幽门可能 引起炎症和不适当的免疫反应。 一个这样 因子是脂多糖(LPS),其已知介导 炎症和诱导细胞因子释放。 O的结构 多糖部分。最近已经阐明了幽门螺杆菌LPS 对于三种不同的菌株;每一种都是独特的, 终止于刘易斯x和/或刘易斯y血型抗原。 H.幽门 第一个发现表达这些刘易斯抗原决定簇的细菌。 刘易斯x和刘易斯在正常胃组织中发现,但更多 在某些肿瘤细胞上大量存在 对H. 在H.幽门螺杆菌感染可以是 考虑了 它们可以(1)作为分子模拟物,使宿主失明 到H.幽门螺杆菌,从而帮助这种病原体逃避免疫 系统;(2)作为粘附素与细胞受体相互作用, 胃粘膜;(3)刺激自身免疫反应,导致组织 损害,从而有助于疾病状态;或(4)引起口腔 耐受性,从而导致宿主清除 也被刘易斯抗原标记的肿瘤。 你们谁也别想 假设是相互排斥的,他们中的任何一个都不会失败。 会对宿主造成伤害。 这一新的H. 幽门螺杆菌研究计划的目的是确定刘易斯抗原在 这种细菌的致病机理和致癌潜力。 建立了H.基于刘易斯抗原的幽门螺杆菌 将建立表达以分型来自各种临床的菌株, 源 此外,H.幽门螺杆菌菌株有效地生产 将构建刘易斯抗原并评估其致病性 其特性及其作为候选疫苗的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joanna B Goldberg其他文献

Joanna B Goldberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joanna B Goldberg', 18)}}的其他基金

Monoclonal Antibody to Combat Pseudomonas Aeruginosa
对抗铜绿假单胞菌的单克隆抗体
  • 批准号:
    10674274
  • 财政年份:
    2023
  • 资助金额:
    $ 15.22万
  • 项目类别:
Pyocins as antibacterials to treat Pseudomonas aeruginosa infections
脓毒素作为抗菌药物治疗铜绿假单胞菌感染
  • 批准号:
    10727705
  • 财政年份:
    2023
  • 资助金额:
    $ 15.22万
  • 项目类别:
Mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa Co-existence in CF
CF中金黄色葡萄球菌和铜绿假单胞菌共存的机制
  • 批准号:
    10078252
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
Impact of Alginate Overproduction on P. aeruginosa LPS O Antigen Expression
海藻酸盐过量生产对铜绿假单胞菌 LPS O 抗原表达的影响
  • 批准号:
    9317789
  • 财政年份:
    2017
  • 资助金额:
    $ 15.22万
  • 项目类别:
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa
EF-Tu对铜绿假单胞菌的磷酸胆酸化机制
  • 批准号:
    8638629
  • 财政年份:
    2014
  • 资助金额:
    $ 15.22万
  • 项目类别:
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa
EF-Tu对铜绿假单胞菌的磷酸胆酸化机制
  • 批准号:
    8912974
  • 财政年份:
    2014
  • 资助金额:
    $ 15.22万
  • 项目类别:
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex
洋葱伯克霍尔德菌复合体中宿主向性的毒力决定因素
  • 批准号:
    8583633
  • 财政年份:
    2013
  • 资助金额:
    $ 15.22万
  • 项目类别:
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex
洋葱伯克霍尔德菌复合体中宿主向性的毒力决定因素
  • 批准号:
    8665382
  • 财政年份:
    2013
  • 资助金额:
    $ 15.22万
  • 项目类别:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
嘌呤生物合成作为幽门螺杆菌感染的治疗靶点
  • 批准号:
    8488407
  • 财政年份:
    2012
  • 资助金额:
    $ 15.22万
  • 项目类别:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
嘌呤生物合成作为幽门螺杆菌感染的治疗靶点
  • 批准号:
    8385961
  • 财政年份:
    2012
  • 资助金额:
    $ 15.22万
  • 项目类别:

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Fellowship
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Research Grant
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Research Grant
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
  • 批准号:
    23H03716
  • 财政年份:
    2023
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis research of anti-Sez6l2 antibody associated encephalopathy
抗Sez6l2抗体相关脑病的分析研究
  • 批准号:
    23K06940
  • 财政年份:
    2023
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了